Biotechnology is a science that is becoming increasingly important in medical research. Developments as important as insulin, gene therapies or vaccines such as hepatitis B have been made possible thanks to this field, which is also present in other areas such as industry, food or the environment.
Within the international panorama, Salamanca has a prominent position thanks to the biosanitary campus of the University of Salamanca and the Institute of Biomedical Research of Salamanca (IBSAL), in addition to a large number of companies that have chosen the town of Salamanca as their main headquarters.
One of them is Neurofix Pharma, a company that develops a drug to alleviate the pain suffered by people with spinal cord injuries and improve their quality of life. Neurofix, led by its CEO and co-founder Miguel Ángel Ávila, specializes in the research and development of innovative therapies for the treatment of pathologies related to the Central Nervous System.
Neuropathic pain is a neurological disorder in which people experience severe chronic pain due to injury or disease of the nervous system. NFX88, the drug developed by Neurofix, is in the final stretch of the Phase II clinical trial, where it is determined whether a new treatment is effective and represents a pioneering alternative that seeks to fill the gap in current treatments for this type of pain derived from spinal cord injuries.
The BISITE Research Group and the AIR Institute are also involved in projects related to the biotechnology area, one of them is DeepNGS, a solution that automates the workflow of genetic analysis and can help in diagnostic procedures. Achieving a higher level of accuracy by incorporating all the patient’s genetic data into a secure, agile and easy-to-use platform.
The fact that this type of development is being carried out in Salamanca represents a boost for our town. It is necessary to support this type of initiatives, either financially or through synergies that allow us to define ourselves as pioneers in medical research.
